ESBL E coli and P. aeruginosa Resistance to Ceftolozane-Tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!

Author(s): Mohamed Teleb, Enrique Soto-Ruiz, Delfina C. Dominguez, Suresh Antony*.

Journal Name: Infectious Disorders - Drug Targets
(Formerly Current Drug Targets - Infectious Disorders)

Volume 18 , Issue 1 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Multi drug resistant (MDR) Pseudomonas aeruginosa and Extended- Spectrum-lactamase (ESBL) Enterobacteriaceae are becoming an increasing difficult clinical problem. Immediate resistance to some of the new antimicrobials such as ceftolozane/tazobactam is unusual and is due to a variety of mechanisms such as hyper-production of inactivating enzymes and gene mutation. In addition, previous antimicrobial administration is a well-recognized risk factor to develop resistance. We present a patient with a liver abscess where the organism was resistant to ceftolozane/tazobactam resulting in a poor clinical outcome.

Keywords: Ceftolozane/Tazobactam, ESBL, gram negative bacteria, mutation, pseudomonas, resistance.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 1
Year: 2018
Page: [81 - 85]
Pages: 5
DOI: 10.2174/1871526516666160713163238
Price: $65

Article Metrics

PDF: 36
HTML: 5
EPUB: 1
PRC: 1

Special-new-year-discount